Gastrointestinal Disorders

Treatment and Prophylaxis

• The American Gastroenterological Association does not recommend Potassium-Competitive Acid Blockers (P-CABs) as first-line therapy for peptic ulcer disease (PUD) treatment or prophylaxis, but they may be useful in proton pump inhibitor (PPI) treatment failures 1
• Vonoprazan 20 mg has shown noninferiority to lansoprazole 30 mg for gastric ulcer healing (94% vs 94%) and duodenal ulcers (96% vs 98%) 1
• First-line treatment for peptic ulcer disease includes proton pump inhibitor (PPI) therapy, with a healing rate of 80-100% of patients within 4 weeks, although larger gastric ulcers may require 8 weeks of treatment 2
• Standard dose PPI once daily for 4-8 weeks is recommended for uncomplicated peptic ulcers, with options including omeprazole 20 mg daily, lansoprazole 30 mg daily, pantoprazole 40 mg daily, rabeprazole 20 mg daily, and esomeprazole 20 mg daily 3, 4
• The maximum recommended oral dosage of proton pump inhibitors is 40 mg twice daily for optimal healing and symptom relief, considered high-dose therapy, according to the American College of Gastroenterology 3, 4

• PPIs vary in relative potency, with the following equivalent doses:

  PPI	Equivalent Dose
  Pantoprazole 40 mg	Omeprazole 9 mg
  Lansoprazole 30 mg	Omeprazole 27 mg
  Esomeprazole 20 mg	Omeprazole 32 mg
  Rabeprazole 20 mg	Omeprazole 36 mg

Bleeding Peptic Ulcers

• P-CABs may have potential benefit for ulcer bleeding due to their rapid and potent acid inhibition, though evidence is still insufficient to recommend them as first-line therapy 1
• Ulcers smaller than 2 cm in diameter are more likely to stop bleeding spontaneously, whereas duodenal ulcers, particularly posterior ones involving the gastroduodenal artery, are less likely to stop bleeding spontaneously and have higher mortality and re-operation rates 4
• Hypotension is an independent predictor of failed spontaneous hemostasis, and risk factors such as age over 60 years, severe medical comorbidities, and concurrent use of other antithrombotic agents or oral corticosteroids warrant long-term PPI therapy while on aspirin 4, 5
• Endoscopic therapy is indicated for specific high-risk lesions (Forrest 1a, 1b, and 2a), and endoscopic intervention is reserved for high-risk lesions or unstable patients, with surgical intervention only needed for refractory bleeding, particularly for ulcers larger than 2 cm, patients with hemodynamic instability, or failed endoscopic treatment 4
• For patients with established cardiovascular diseases, the American Gastroenterological Association recommends continuing aspirin therapy rather than discontinuing it after endoscopic hemostasis, and patients taking aspirin with a history of upper GI bleeding are at high risk for recurrent bleeding events and should not have their PPI discontinued 6, 5
• High-dose PPI therapy is recommended for bleeding peptic ulcers, with initial IV therapy: 80 mg bolus followed by 8 mg/h continuous infusion for 72 hours, and followed by oral therapy: 40 mg twice daily for 6-8 weeks, as per the American College of Surgeons guidelines 4
• Mechanical therapy with epinephrine injection for active bleeding is suggested for bleeding ulcers, and non-aggressive irrigation for adherent clots rather than mechanical dislodgment is suggested for bleeding ulcers 4

H. pylori Eradication

• H. pylori eradication reduces ulcer recurrence from 50-60% to 0-2%, and is typically achieved with standard triple therapy: PPI + clarithromycin + amoxicillin for 14 days, as suggested by the European Helicobacter Study Group 2
• Alternative regimens for areas with high clarithromycin resistance include sequential therapy or bismuth quadruple therapy, according to the World Journal of Emergency Surgery and the American Gastroenterological Association guidelines 4, 7
• The World Journal of Emergency Surgery recommends the following regimens:
  • Standard triple therapy: PPI standard dose twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1000 mg twice daily, for a duration of 14 days 4
  • Sequential therapy: days 1-5 consisting of PPI and amoxicillin, and days 6-10 consisting of PPI, clarithromycin, and metronidazole 4
  • Levofloxacin-amoxicillin triple therapy: PPI standard dose twice daily, levofloxacin 500 mg once daily or 250 mg twice daily, and amoxicillin 1000 mg twice daily, for a duration of 10 days 4

Follow-up and Monitoring

• Treatment duration for uncomplicated peptic ulcers is 4-8 weeks (longer for gastric ulcers), for H. pylori eradication is 14 days of PPI with appropriate antibiotics, and for post-bleeding is 6-8 weeks of PPI therapy, according to the American College of Gastroenterology 4
• Outpatient follow-up within 1-2 weeks, with confirmatory testing for H. pylori eradication 4 weeks after completing therapy, and consider endoscopic follow-up in 8-12 weeks to confirm healing and rule out malignancy for gastric ulcers, as recommended by guidelines from organizations such as the American Gastroenterological Association 4
• Long-term PPI therapy is not recommended unless ongoing NSAID use is necessary, and monitoring for potential PPI adverse effects is essential, as recommended by the World Journal of Emergency Surgery guidelines 4